New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2013
08:34 EDTISISIsis Pharmaceuticals expects 2013 to be year of substantial growth, maturation
Expects initial commercial launch of Kynamro to be successful. The company added, ""Beyond Kynamro, we have a number of drugs in our pipeline that will complete later-stage clinical studies, which are designed to provide clear evidence that these drugs have the potential to work in patients in numerous different diseases. In addition, we plan to advance many other drugs in our pipeline, creating additional opportunities for significant long-term revenue. And finally, we expect to explore partnering opportunities that are the right fit for Isis and designed to provide the most benefit to our programs and drugs, the best balance of risk and commercial participation, while allowing us to continue to do what we do best, drug discovery and early drug development."
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
07:09 EDTISISIsis Pharmaceuticals initiates pivotal Phase 3 study evaluating ISIS-SMN
Subscribe for More Information
November 20, 2014
07:24 EDTISISGoldman to hold a conference
Subscribe for More Information
06:40 EDTISISIsis Pharmaceuticals price target raised to $62 from $53 at Piper Jaffray
Subscribe for More Information
November 18, 2014
15:48 EDTISISGenzyme, Isis present KYNAMRO data at AHA meeting
Genzyme, a Sanofi (SNY) company, and Isis Pharmaceuticals (ISIS) announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
November 14, 2014
15:41 EDTISISIsis Pharmaceuticals management to meet with Piper Jaffray
Meeting to be held in Kansas City, MO on November 18 hosted by Piper Jaffray.
November 13, 2014
05:34 EDTISISAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
07:53 EDTISISLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use